Published in Eur Urol on January 01, 2008
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol (2014) 2.78
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2013) 2.74
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol (2009) 2.67
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma. J Urol (2002) 2.23
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis (2009) 2.17
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Readmissions after major urologic cancer surgery. Can J Urol (2014) 2.05
To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy. J Urol (2012) 2.01
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. Am J Surg Pathol (2010) 1.61
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int (2015) 1.47
Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol (2007) 1.45
Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology (2011) 1.43
Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol (2010) 1.39
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol (2009) 1.38
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease. Urology (2004) 1.26
The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design. Cancer Causes Control (2013) 1.26
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology (2007) 1.18
Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med (2009) 1.17
Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care. Urology (2003) 1.17
Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology (2014) 1.13
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer (2013) 1.05
Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol (2009) 1.03
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res (2011) 1.01
Ureteral injury in laparoscopic gynecologic surgery. Rev Obstet Gynecol (2012) 1.01
The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol (2008) 0.99
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int (2015) 0.97
Prostate cancer: screening, diagnosis and management in 2007. Mo Med (2007) 0.97
Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer (2014) 0.96
Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology (2008) 0.95
The role of systemic cytotoxic therapy for prostate cancer. BJU Int (2008) 0.94
Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int (2013) 0.91
Selective versus nonselective arterial clamping during laparoscopic partial nephrectomy: impact upon renal function in the setting of a solitary kidney in a porcine model. J Endourol (2009) 0.91
Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate (2006) 0.90
Rapid resolution of carbon dioxide pneumothorax (capno-thorax) resulting from diaphragmatic injury during laparoscopic nephrectomy. J Urol (2002) 0.90
Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res (2013) 0.89
The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol (2009) 0.88
Management of the postpubertal patient with cryptorchidism: an updated analysis. J Urol (2002) 0.87
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment. J Urol (2012) 0.87
Targeting the androgen receptor--theory and practice. Urology (2011) 0.85
The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011. World J Surg (2015) 0.84
Trends in nephron-sparing surgery for renal neoplasia. Urology (2006) 0.84
Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer (2002) 0.83
High-risk localized prostate cancer: role of radical prostatectomy. Curr Opin Urol (2010) 0.83
Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int (2014) 0.82
Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer Immunol Immunother (2015) 0.81
BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol (2010) 0.81
Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urol Oncol (2011) 0.80
Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate (2010) 0.80
Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update. J Endourol (2011) 0.80
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev (2013) 0.79
Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol (2012) 0.79
Preventable mortality after common urological surgery: failing to rescue? BJU Int (2014) 0.79
Minimally invasive approaches to localized prostate carcinoma. Hematol Oncol Clin North Am (2006) 0.79
Treat now or later: the dilemma of postoperative radiotherapy. Eur Urol (2011) 0.79
Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). BJU Int (2014) 0.79
Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. Cancer (2014) 0.79
Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. Ann Surg (2015) 0.79
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer (2016) 0.78
Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma. Cancer (2008) 0.78
Optimizing prostate biopsy techniques. J Urol (2007) 0.78
Indications and practice with androgen deprivation therapy. Urology (2011) 0.77
Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg (2009) 0.77
Positive margin during partial nephrectomy: does cancer remain in the renal remnant? Urology (2011) 0.77
Early detection, PSA screening, and management of overdiagnosis. Hematol Oncol Clin North Am (2013) 0.76
The use and abuse of data: nomograms and talking to patients about clinical medicine. Urol Oncol (2007) 0.76
Chronic kidney disease and perioperative outcomes in urological oncological surgery. Int J Urol (2014) 0.76
Words of wisdom. Re: active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. Eur Urol (2011) 0.75
Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50". Cancer (2010) 0.75
Counterpoint: Prostate carcinoma treatment for the young patient--The case for radical prostatectomy. Brachytherapy (2010) 0.75
Editorial comment. J Urol (2013) 0.75
Editorial comment. J Urol (2009) 0.75
Words of wisdom. Re: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. Eur Urol (2009) 0.75
Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing? Eur Urol (2012) 0.75
Words of wisdom. Re: Intermittent androgen suppression for rising PSA level after radiotherapy. Eur Urol (2013) 0.75
Editorial comment. J Urol (2009) 0.75
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol (2015) 0.75
The Second Joint Meeting of American Urological Association (AUA)/Japanese Urological Association (JUA) International Program on the 102nd Annual Meeting of American Urological Association at Anaheim 2007. Int J Urol (2007) 0.75
Parenchymal imaging adds diagnostic utility in evaluating haematuria. BJU Int (2005) 0.75
Open versus laparoscopic retroperitoneal lymph node dissection: assessing adequacy of dissection in a porcine model. J Endourol (2009) 0.75
Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Can J Urol (2017) 0.75
Highlights of the 2010 SUO Annual Meeting. Urol Oncol (2011) 0.75